Insider Selling: Takeda Pharmaceutical (NYSE:TAK) Insider Sells $429,004.80 in Stock

Takeda Pharmaceutical Co. (NYSE:TAK) insider Gabriele Ricci sold 25,088 shares of the stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $17.10, for a total transaction of $429,004.80. Following the transaction, the insider owned 171,654 shares in the company, valued at approximately $2,935,283.40. The trade was a 12.75% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Takeda Pharmaceutical Stock Up 1.5%

Shares of TAK opened at $17.64 on Friday. Takeda Pharmaceutical Co. has a 12 month low of $12.99 and a 12 month high of $18.90. The firm’s 50 day moving average is $16.57 and its 200-day moving average is $17.14. The stock has a market capitalization of $56.53 billion, a PE ratio of 51.89 and a beta of -0.08. The company has a current ratio of 1.14, a quick ratio of 0.62 and a debt-to-equity ratio of 0.58.

Takeda Pharmaceutical (NYSE:TAK) last released its quarterly earnings results on Tuesday, March 31st. The company reported $0.56 earnings per share for the quarter. The company had revenue of $6.90 billion during the quarter. Takeda Pharmaceutical had a net margin of 3.80% and a return on equity of 10.95%. Equities research analysts forecast that Takeda Pharmaceutical Co. will post 0.32 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the company. Private Trust Co. NA raised its position in Takeda Pharmaceutical by 84.7% during the fourth quarter. Private Trust Co. NA now owns 1,707 shares of the company’s stock valued at $27,000 after purchasing an additional 783 shares in the last quarter. Parkside Financial Bank & Trust boosted its holdings in shares of Takeda Pharmaceutical by 192.2% in the 4th quarter. Parkside Financial Bank & Trust now owns 2,560 shares of the company’s stock valued at $40,000 after purchasing an additional 1,684 shares in the last quarter. SHP Wealth Management acquired a new stake in shares of Takeda Pharmaceutical in the 4th quarter valued at $42,000. Caitong International Asset Management Co. Ltd increased its stake in shares of Takeda Pharmaceutical by 313.7% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 3,070 shares of the company’s stock valued at $48,000 after purchasing an additional 2,328 shares during the last quarter. Finally, Northwestern Mutual Wealth Management Co. increased its stake in shares of Takeda Pharmaceutical by 56.3% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 3,586 shares of the company’s stock valued at $55,000 after purchasing an additional 1,292 shares during the last quarter. 9.17% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on TAK. Zacks Research raised Takeda Pharmaceutical from a “strong sell” rating to a “hold” rating in a report on Tuesday, August 4th. Weiss Ratings lowered Takeda Pharmaceutical from a “hold (c-)” rating to a “sell (d+)” rating in a report on Thursday, July 30th. Finally, Wall Street Zen upgraded Takeda Pharmaceutical from a “hold” rating to a “buy” rating in a research report on Saturday, July 18th. Two equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Takeda Pharmaceutical presently has a consensus rating of “Hold”.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.